Rbm24, a target of p53, is necessary for proper expression of p53 and heart development

被引:68
|
作者
Zhang, Min [1 ,2 ,3 ]
Zhang, Yanhong [1 ,2 ]
Xu, Enshun [1 ,2 ]
Mohibi, Shakur [1 ,2 ]
de Anda, Danielle Michelle [1 ,2 ]
Jiang, Yuqian [1 ,2 ]
Zhang, Jin [1 ,2 ]
Chen, Xinbin [1 ,2 ]
机构
[1] Univ Calif Davis, Comparat Oncol Lab, Sch Vet Med, Davis, CA 95616 USA
[2] Univ Calif Davis, Comparat Oncol Lab, Sch Med, Davis, CA 95616 USA
[3] Huazhong Agr Univ, Coll Life Sci & Technol, Wuhan, Hubei, Peoples R China
来源
CELL DEATH AND DIFFERENTIATION | 2018年 / 25卷 / 06期
关键词
RNA-BINDING PROTEIN; IMPROVES CARDIAC-FUNCTION; REGULATES P63 EXPRESSION; ENDOCARDIAL CUSHION; CARDIOMYOCYTE APOPTOSIS; PUMA; TRANSLATION; DELETION; FAILURE; FAMILY;
D O I
10.1038/s41418-017-0029-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Activation of p53-dependent apoptosis is critical for tumor suppression but aberrant activation of p53 also leads to developmental defects and heart failure. Here, we found that Rbm24 RNA-binding protein, a target of p53, regulates p53 mRNA translation. Mechanistically, we found that through binding to p53 mRNA and interaction with translation initiation factor eIF4E, Rbm24 prevents eIF4E from binding to p53 mRNA and inhibits the assembly of translation initiation complex. Importantly, we showed that mice deficient in Rbm24 die in utero due to the endocardial cushion defect in the heart at least in part due to aberrant activation of p53-dependent apoptosis. We also showed that the heart developmental defect in Rbm24-null mice can be partially rescued by p53 deficiency through decreased apoptosis in the heart. Together, we postulate that the p53-Rbm24 loop is critical for the heart development and may be explored for mitigating congenital heart diseases and heart failure.
引用
收藏
页码:1118 / 1130
页数:13
相关论文
共 50 条
  • [31] RBM10, a New Regulator of p53
    Jung, Ji Hoon
    Lee, Hyemin
    Zeng, Shelya X.
    Lu, Hua
    CELLS, 2020, 9 (09) : 1 - 13
  • [32] p53 as a therapeutic target for the development of anticancer drugs
    Bouchet, Benjamin Pierre
    de Fromentel, Claude Caron
    Galmarini, Carlos Maria
    Puisieux, Alain
    BULLETIN DU CANCER, 2006, 93 : 145 - 153
  • [33] p53 family in development
    Danilova, Nadia
    Sakamoto, Kathleen M.
    Lin, Shuo
    MECHANISMS OF DEVELOPMENT, 2008, 125 (11-12) : 919 - 931
  • [34] p53 as a target in myeloproliferative neoplasms
    Lu, Min
    Hoffman, Ronald
    ONCOTARGET, 2012, 3 (10) : 1052 - 1053
  • [35] p53 Protein expression and p53 mutation in thymic epithelial tumors - Reply
    Tateyama, H
    Eimoto, T
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1996, 105 (05) : 658 - 658
  • [36] p53 heterozygosity alters the mRNA expression of p53 target genes in the bone marrow in response to inhaled benzene
    Boley, SE
    Wong, VA
    French, JE
    Recio, L
    TOXICOLOGICAL SCIENCES, 2002, 66 (02) : 209 - 215
  • [37] A circuitous way to target p53
    Sarah Seton-Rogers
    Nature Reviews Cancer, 2015, 15 : 318 - 319
  • [38] A circuitous way to target p53
    Seton-Rogers, Sarah
    NATURE REVIEWS CANCER, 2015, 15 (06) : 318 - 318
  • [39] p53 as a target for the treatment of cancer
    Duffy, Michael J.
    Synnott, Naoise C.
    McGowan, Patricia M.
    Crown, John
    O'Connor, Darran
    Gallagher, William M.
    CANCER TREATMENT REVIEWS, 2014, 40 (10) : 1153 - 1160
  • [40] The role of the 5' terminal region of p53 mRNA in the p53 gene expression
    Swiatkowska, Agata
    Zydowicz, Paulina
    Sroka, Joanna
    Ciesiolka, Jerzy
    ACTA BIOCHIMICA POLONICA, 2016, 63 (04) : 645 - 651